4basebio to Supply Synthetic DNA for Planned Cell Therapy Trial

MT Newswires · 2d ago
04:47 AM EDT, 09/28/2026 (MT Newswires) -- Synthetic DNA manufacturer 4basebio (4BB.L) will supply clinical-grade opDNA starting material for a pharmaceutical company's phase I cell therapy program. For the clinical trial, contract development and manufacturing organization TriLink BioTechnologies will manufacture the mRNA drug substance, according to a Monday release.